Access cutting-edge glioma treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access glioma specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related glioma treatment provided free
This is a 2-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 3 astrocytoma with high-risk features or Grade 4 IDH1-mutant astrocytoma, following standard-of-care radi
Sponsor: Nuvation Bio Inc.
Check if you qualify for this glioma clinical trial in Los Angeles, CA
If you're searching for glioma treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.